A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's

Plasma Amyloid Beta Species After a Single Solanezumab Infusion in Nondemented Individuals and Those With Mild Dementia of the Alzheimer's Type

The purpose of this trial is to compare the average change in the amount of amyloid beta species in blood after an infusion of solanezumab.

Study Overview

• Status: Completed
• Conditions: Alzheimer's Disease
• Intervention / Treatment: Drug: solanezumab

• Study Type: Interventional
• Enrollment (Anticipated): 55
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Missouri
    • St. Louis, Missouri, United States, 63108
      • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 90 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Individuals in Groups 1, 2, and 3, described below, will be participants in the longitudinal studies of memory and aging at the Washington University Alzheimer's Disease Research Center (WU-ADRC). These participants must have results from apolipoprotein E (ApoE) genotyping from the WU-ADRC. At the beginning of the study they must be between 45 and 90 years of age and if a female of childbearing potential, not be breastfeeding, test negative for pregnancy, and be using a medically accepted form of birth control at the time of the infusion and for 6 months afterward. Subjects must also meet the criteria below for each study group

Group 1, Mild dementia of Alzheimer's type (DAT):

• Have mild DAT, as determined by Clinical Dementia Rating (CDR) of 0.5 or 1
• Have florbetapir PET imaging findings consistent with underlying AD pathology.

Group 2, Older Adult Controls with Possible AD Pathology:

Have no cognitive impairment as indicated by a CDR rating of 0. Have possible AD pathology, as determined by florbetapir PET imaging.

Group 3, Older Adult Controls with No Evidence of AD Pathology:

Have no cognitive impairment as indicated by a CDR rating of 0. Have no evidence of AD pathology as determined by florbetapir PET imaging.

Individuals recruited into Group 4 will not be participants in the longitudinal studies of memory and aging at WU-ADRC. To be included in Group 4, individuals must meet these criteria:

• Are at least 18 years and <35 years of age at the beginning of the study and if a female of childbearing potential, is not breastfeeding, tests negative for pregnancy and is using highly effective contraception at the time of the solanezumab infusion and for 6 months following infusion
• Have a Folstein Mini-Mental State Examination (MMSE) score of 29 to 30 at the beginning of the study

Exclusion Criteria:

• Have previously completed or withdrawn from this study or any other study investigating solanezumab
• Does not have good venous access, such that intravenous drug delivery or multiple blood draws would be precluded
• Has allergies to humanized monoclonal antibodies
• Has a known history of human immunodeficiency virus (HIV), clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear IgA dermatosis, toxic epidermal necrolysis, or exfoliative dermatitis)
• Has a history of chronic alcohol or drug abuse/dependence
• Is clinically judged by the investigator to be at serious risk for suicide
• Has a recent (within 6 months before screening) or current laboratory result (if available) indicating a clinically significant laboratory abnormality
• Has Electrocardiogram (ECG) abnormalities obtained at screening that, in the opinion of the investigator, are clinically significant with regard to the subject's participation in the study. Bazett's corrected QT [QTcB] interval must be evaluated and must not exceed >458 msec in males or >474 msec in females
• At screening, has alanine transaminase (ALT/SGPT) values greater than or equal to 2 times the upper limit of normal (ULN) of the performing laboratory, aspartate transaminase (AST/SGOT) values greater than or equal to 3 times the ULN, or total bilirubin values greater than or equal to 2 times the ULN
• Has had IgG therapy (sometimes called gamma globulin therapy) within the last year or previous participation in any other study investigating active immunization against Aβ
• Requires treatment with other monoclonal antibodies

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group 1; Older adults with mild Dementia Alzheimer's Type (DAT)	Drug: solanezumab; 400mg administered once intravenously; Other Names: LY2062430; A Beta Antibody
Experimental: Group 2; Older adult controls with possible Alzheimer's Disease Pathology	Drug: solanezumab; 400mg administered once intravenously; Other Names: LY2062430; A Beta Antibody
Experimental: Group 3; Older adult controls with no evidence of Alzheimer's Disease	Drug: solanezumab; 400mg administered once intravenously; Other Names: LY2062430; A Beta Antibody
Experimental: Group 4; Younger subjects who are assumed to have no cognitive impairment	Drug: solanezumab; 400mg administered once intravenously; Other Names: LY2062430; A Beta Antibody

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Mean change from baseline up to 112 days post drug administration in plasma levels of Aβ fragment-2 in (Group 1) and (Group 3)	Baseline up to 112 days post drug administration

Secondary Outcome Measures

Outcome Measure	Time Frame
Mean change in plasma levels of Aβ1-42 after solanezumab infusion	Baseline (pre-dose); 30 minutes; 24 hours; 7, 28, 56 and 112 days post-dose
Mean change in plasma levels of Aβ1-40 species after solanezumab infusion	Baseline (pre-dose); 30 minutes; 24 hours; 7, 28, 56 and 112 days post-dose
Mean change in plasma levels of modified Aβ species after solanezumab infusion	Baseline (pre-dose); 30 minutes; 24 hours; 7, 28, 56 and 112 days post-dose

Collaborators and Investigators

• Sponsor: Eli Lilly and Company

Study record dates

Study Major Dates

• Study Start: August 1, 2010
• Primary Completion (Actual): August 1, 2012
• Study Completion (Actual): August 1, 2012

Study Registration Dates

• First Submitted: June 18, 2010
• First Submitted That Met QC Criteria: June 18, 2010
• First Posted (Estimate): June 22, 2010

Study Record Updates

• Last Update Posted (Estimate): September 25, 2012
• Last Update Submitted That Met QC Criteria: September 18, 2012
• Last Verified: August 1, 2012

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurocognitive Disorders; Neurodegenerative Diseases; Dementia; Tauopathies; Alzheimer Disease
• Other Study ID Numbers: 13572; H8A-MC-LZAT (Other Identifier: Eli Lilly and Company)